07:33 AM EST, 03/07/2024 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) reported a Q4 net loss of $0.33 per diluted share, narrower than its loss of $1.16 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.49 per share.

Revenue for the quarter ended Dec. 31 was $14 million, up from $10.5 million a year earlier.

Analysts surveyed by Capital IQ expected $8.7 million.

The biopharmaceutical company reported it had $331.1 million in cash, cash equivalents, and marketable securities as of Dec. 31, sufficient to fund operations through 2026.

EyePoint Pharmaceuticals' ( EYPT ) shares were up nearly 5% in recent Thursday premarket activity.

Price: 27, Change: +1.26, Percent Change: +4.9